| 51 |
31375130 | Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. | 2019 Aug 2 |
1 |
| 52 |
31401212 | The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. | 2019 Sep |
1 |
| 53 |
31642025 | Upadacitinib: First Approval. | 2019 Nov |
2 |
| 54 |
31654328 | Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation. | 2019 Oct 25 |
1 |
| 55 |
31732180 | Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. | 2019 Dec 7 |
1 |
| 56 |
31791386 | Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. | 2019 Dec 2 |
1 |
| 57 |
28762476 | Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity. | 2018 May |
1 |
| 58 |
29076110 | Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. | 2018 Aug |
1 |
| 59 |
29908669 | Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. | 2018 Jun 23 |
1 |
| 60 |
29908670 | Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. | 2018 Jun 23 |
2 |
| 61 |
28503781 | Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. | 2017 Oct |
1 |
| 62 |
27272171 | Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. | 2016 Dec |
2 |
| 63 |
27389975 | A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. | 2016 Dec |
2 |
| 64 |
27390150 | Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. | 2016 Dec |
2 |